

10/551929

1

JC20 Rec'd PCT/PTO 05 OCT 2005

**METHOD OF SCREENING THE OPERATING CONDITIONS OF A  
CHEMICAL COUPLING REACTION AND KITS FOR CARRYING OUT  
THIS METHOD**

5

**DESCRIPTION**

This patent application claims the priority  
of the French patent application filed on  
April 15, 2003 under no. 03 50106 which is incorporated  
10 hereby by reference.

**TECHNICAL FIELD**

The present invention relates to a method  
of screening the operating conditions of a chemical  
15 coupling reaction, and also to kits suitable for  
allowing this method to be carried out.

More precisely, it relates to a method for  
simultaneously testing the effects of various operating  
conditions on the yield of a reaction consisting in  
20 coupling at least two functional groups with a view,  
for example, to selecting the one or those of these  
conditions that result in optimization of this yield.

These operating conditions may be both  
qualitative and quantitative.

25 Thus, the method can be used to screen  
substances, such as catalysts or solvents, for which it  
is desired to determine whether they are capable of  
being useful in a particular coupling reaction, but it  
may also be used for screening levels, for example  
30 temperature or pressure levels, concentrations,  
stoichiometric ratios or times, such as reaction time

or stirring time for the reaction medium, for which it is desired to determine the influence on the yield of a coupling reaction.

The method according to the invention is therefore liable to find a large number of applications in the field of research, both fundamental and applied.

Thus, for example, it can be used in fundamental studies aimed at a better understanding of the mechanisms of homogeneous or heterogeneous catalysis, whether chemical or biological.

It can also be used in applied research studies, in particular in the areas of chemistry, agrofoods, pharmacy and in environmental protection, having the aim either of developing catalysts that are more effective and more able to respond specifically to particular constraints, or of optimizing synthesis reaction yields or experimental conditions, with a view, for example, to a decrease in the costs of carrying out these reactions.

In particular, it can be used to screen a library of mutated enzymes in order to improve the catalytic performance levels of a "wild-type" enzyme, or to screen biological media that have a known or unknown composition, with the aim of identifying the existence of a particular catalytic activity in these media.

#### STATE OF THE PRIOR ART

In terms of screening the operating conditions of a coupling reaction, these are

essentially methods intended to screen catalysts that have been proposed to date.

These methods all comprise a step consisting in reacting two particular compounds, representative of the families of compounds for which the coupling reaction is liable to be used, in the presence of the various candidate catalysts, followed by a step consisting in assessing the effectiveness of these catalysts on said reaction.

Thus, firstly, there are known methods that aim to analyze, at the end of the coupling reaction, the composition of the reaction media by high pressure liquid chromatography (HPLC), which means that they must first be purified, for example by filtration on silica gel columns.

These are therefore methods that are laborious to carry out, that allow only a limited number of tests to be carried per day, and that are, consequently, completely unsuitable for medium- or high-throughput screening.

Secondly, there are existing methods that aim to use, at the end of the coupling reaction, a chemical reaction which is capable of reacting either with one of the compounds involved in this coupling reaction, or with the product or a by-product derived from said reaction, generating a signal such as a coloration, a decoloration, or the emission of a fluorescence or of a chemoluminescence.

By way of examples, mention may be made of:

- the method described by Lavastre and Morken in *Angew. Chem. Int. Ed.*, 1999, 38(21), 3163-

3165, [1], for screening catalysts that are useful in an allylic alkylation, and which aims to detect the 1-naphthol produced in the course of this alkylation by reacting it with the diazonium salt known as "Fast Red Violet LB", so as to turn it bright orange;

- that described by Böhm and Herrmann in *Eur. J. Org. Chem.*, 2000, 3679-3681, [2], for screening catalysts that are useful in the Sonogashira reaction, and which consists in revealing the product of this reaction by oxidizing it with  $\text{KMnO}_4$ , which causes a decoloration of the reaction media; and

- that proposed by Löber et al. in *J. Am. Chem. Soc.*, 2001, 123, 4366-4367, [3], for screening catalysts that are useful in the hydroamination of 1,3-dienes by arylamines such as aniline, and which consists in revealing the residual aniline by reacting it with furfural in the presence of an acid, the effect of which is to colour the reaction media red.

This second type of method exhibits, itself, the drawback of requiring reactants that are specific for one of the compounds involved in the coupling reaction or for the product formed by this reaction, which limits its use to the screening of reactions involving compounds or resulting in products for which such reactants are available.

There are also existing methods in which one of the compounds involved in the coupling reaction is attached to a solid support, while the other is labelled with a fluorescent probe. Since the two compounds are reacted, the effectiveness of the catalysis results in the formation on the solid support

of the product derived from the reaction. This support must then be washed in order to eliminate the fraction of compounds that have not reacted and to detect the product derived from the reaction by reading the fluorescence present on said support.

An example of these methods is illustrated in the article by Shaugnessy et al. (*J. Am. Chem. Soc.*, 1999, 121, 2123-2132, [4]), for screening catalysts that are useful in the Heck reaction. In this example, the first compound is an aryl halide that is attached to a crosslinked polystyrene resin (Wang resin), while the second compound is an acrylate labelled with coumarin.

The latter type of method exhibits two major drawbacks. First of all, the catalysis is carried out in a heterogeneous medium. Now, it is known that a catalyst that shows high catalytic activity in a heterogeneous medium can prove to be entirely ineffective in homogeneous medium. Moreover, the assessment of the catalysis is essentially qualitative, in that it is difficult to calculate the yield of the coupling reaction since this calculation would require knowledge of the degree of grafting of the first compound on the solid support.

Yet another type of method is based on the fact that, in the presence of an effective catalyst, the release of heat by a reaction occurs more rapidly than in the presence of an ineffective catalyst. Thus, it is possible to assess the effectiveness of catalysts by measuring the temperature variation of the reaction media, either by calorimetry or by thermography using

ultrasensitive infrared cameras fixed above said reaction media.

An example of an embodiment of this type of method is illustrated in the publication by Blackmond  
5 et al. (*Organic Process Research & Development*, 1999, 3(4), 275-280, [5]), for screening catalysts that are useful in the Heck reaction.

Thermal analysis screening methods have the deficiency of requiring substantial and expensive  
10 material. Moreover, they do not make it possible to calculate the reaction yield. Finally, they are not applicable to reactions that take place slowly and that, as a result, give off amounts of heat that are not detectable or sufficiently significant.

Finally, is has been proposed, by  
15 Hinderling and Chen in *Angew. Chem. Int. Ed.*, 1999, 38(15), 2253-2256, [6], to use electrospray mass spectrophotometry for carrying out the screening of olefin polymerization catalysts. Here also, it involves  
20 a method that requires substantial and expensive equipment.

There exists therefore a real need for a method that makes it possible to test the effects of various operating conditions on a coupling reaction,  
25 and more particularly the potential usefulness of catalysts in this reaction, and that, in general, is free of all the drawbacks exhibited by the screening methods proposed to date.

**DISCLOSURE OF THE INVENTION**

The present invention satisfies precisely this need by providing a method of screening the operating conditions of a coupling reaction of at least  
5 two functional groups, which comprises the following steps:

i) reacting together at least two compounds:

• a first compound of formula  $E_1-X_1-G_1$  in which  $G_1$   
10 represents a first of said at least two functional groups,  $X_1$  represents a covalent bond or a first spacer group, while  $E_1$  represents the residue of a first molecule  $M_1$  for which a first specific antibody  $AC_1$  is available, and

15 • a second compound of formula  $E_2-X_2-G_2$  in which  $G_2$  represents a second of said at least two functional groups,  $X_2$  represents a covalent bond or a second spacer group, which may be identical to or different from  $X_1$ , while  $E_2$  represents either the residue of a  
20 second molecule  $M_2$  that is different from  $M_1$  and for which a second specific antibody  $AC_2$  is available, or a group capable of forming at least one covalent bond with the antibody  $AC_1$  in the presence of a coupling agent;

25 said at least two compounds being reacted in solution in a solvent and under predetermined operating conditions, at least one of which is a candidate operating condition, in order to obtain a reaction medium and the formation, in this medium, of a compound  
30 Z comprising the chain  $E_1-X_1-G_1-G_2-X_2-E_2$  in which  $X_1$ ,  $X_2$ ,  $E_1$  and  $E_2$  have the same meaning as above, while  $G_1-G_2$

represents the group of atoms resulting from the coupling of said at least two functional groups;

5 ii) determining the concentration of compound Z in the reaction medium at a predetermined reaction time  $t$ , by means of at least one immunoassay using at least the antibody  $AC_1$ ; and

10 iii) evaluating the effects of the candidate operating condition(s) on said coupling reaction using the concentration of compound Z thus determined.

Thus, in the method according to the invention, the coupling reaction, for which it is desired to screen the operating conditions and which involves a minimum of two functional groups, in the case in point  $G_1$  and  $G_2$ , is carried out using, as  
15 reactants, at least two compounds which each comprise, at one end, one of these functional groups and, at the other end, the residue of a molecule, respectively  $M_1$  and  $M_2$ , for which a specific antibody, respectively  $AC_1$  and  $AC_2$ , is available or, in the case of the second  
20 compound, a group capable of forming one or more covalent bonds with the antibody  $AC_1$  specific for the molecule  $M_1$  in the presence of a coupling agent.

The concentration, in the reaction medium, of compound Z produced by the coupling reaction can thus be readily determined, at a selected reaction time  $t$ , by means of at least one immunoassay, this assay using either only the antibody  $AC_1$ , or the two  
25 antibodies  $AC_1$  and  $AC_2$ .

30 Once the concentration of compound Z is known, it is then possible to determine, by means of a



calculation, the yield of the coupling reaction and to assess the effects of the operating conditions under which it has been carried out, by means of the value of this yield. These effects can, however, also be  
5 assessed by comparing said concentration with one or more concentrations obtained beforehand under different operating conditions and acting as reference values.

In the above and following text:

- the term "candidate operating condition"  
10 is intended to mean an operating condition for which the effects on the coupling reaction are tested;

- the term "residue" of a molecule  $M_1$  is intended to mean the part of this molecule that remains in the compound of formula  $E_1-X_1-G_1$  when said molecule  
15 is covalently attached either to functional group  $G_1$ , or to the spacer group, depending on whether  $X_1$  represents a covalent bond or a spacer group; similarly, the term "residue" of a molecule, respectively  $M_2$ ,  $M_3$  or  $M_4$ , corresponds to the part of  
20 this molecule that remains in the compound of formula  $E_2-X_2-G_2$ ,  $E_3-X_3-G_3$  or  $E_4-X_4-G_4$ , respectively, when said molecule is covalently attached either to the functional group  $G_2$ ,  $G_3$  or  $G_4$ , respectively, or to the spacer group, depending on whether  $X_2$ ,  $X_3$  or  $X_4$   
25 represents a covalent bond or a spacer group.

Moreover, the term "antibody specific" for a molecule is intended to mean an antibody capable of specifically recognizing this molecule and of binding with it by means of an antigen-antibody immunoreaction.

30 As indicated above, in the compounds  $E_1-X_1-G_1$  and  $E_2-X_2-G_2$ ,  $G_1$  and  $G_2$  correspond to the two

functional groups which are at least involved in the coupling reaction for which it is desired to screen the operating conditions, and are therefore chosen according to this reaction.

5                   Coupling reactions involving two functional groups and for which the method according to the invention can be used are in particular the following intermolecular coupling reactions:

                  - esterification reactions such as those  
10   which consist in coupling a carboxylic acid ( $R\text{-COOH}$ ) or a carboxylic acid derivative such as, for example, an acid halide ( $R\text{-CO-Hal}$ ), and an alcohol ( $R'\text{-OH}$ ) so as to obtain an ester group ( $R\text{-CO}_2R'$ );

                  - amidation reactions such as those which  
15   consist in coupling a carboxylic acid ( $R\text{-COOH}$ ) or a carboxylic acid derivative and a primary ( $R'\text{-NH}_2$ ) or secondary ( $R'\text{-NH-R''}$ ) amine so as to obtain an amide ( $R\text{-CONH-R'}$  or  $R\text{-CONR'-R''}$ );

                  - aldolization reactions such as those  
20   which consist in coupling two aldehydes ( $R\text{-CHO}$ ) or two ketones ( $R\text{-CO-R'}$ ), or in coupling an aldehyde and a ketone so as to obtain an aldol or a ketol, and variants thereof such as the nitroaldolization reaction in which an aldehyde is coupled to a nitrogenous  
25   compound ( $R'\text{-CH}_2\text{-NO}_2$ ) so as to obtain a nitro alcohol ( $R\text{-CH(OH)-CH(NO}_2\text{)-R'}$ );

                  - the Heck reaction, which consists in  
coupling an olefin ( $R'\text{-CH=CH}_2$ ) and an organic halide ( $R'\text{-Hal}$ ) so as to obtain an alkene ( $R\text{-CH=CH-R'}$ ), and its  
30   variants;

- the Baylis-Hillman reaction, which consists in coupling an alkene ( $R-CH=CH_2$ ) and an aldehyde ( $R'-CHO$ ) so as to obtain an allyl alcohol ( $R'-C(CH_2)-CH(OH)-R'$ ), and its variants;
- 5        - the Michael reaction, which consists of an addition between a nucleophilic compound and an unsaturated electron-acceptor compound (for example,  $R-CH=CH_2$ ), and its variants;
- metathesis reactions such as those which
- 10       consist in coupling two olefins (for example,  $R-CH=CH_2$  and  $R'-CH=CH_2$ ) so as to obtain a third thereof ( $R-CH=CH-R'$ );
- the Diels-Alder reaction, which consists of a cycloaddition between a diene and a dienophile;
- 15       - the Sonogashira reaction, which consists in coupling an alkyne ( $R-C\equiv CH$ ) and an aryl halide ( $Ar-Hal$ ) so as to obtain an arylalkyne ( $R-C\equiv C-Ar$ ), and its variants;
- the Suzuki reaction, which consists in
- 20       coupling an arylboronic acid ( $Ar-B(OH)_2$ ) and an aryl halide ( $Ar'-Hal$ ) so as to obtain a diaryl ( $Ar-Ar'$ ), and its variants;
- the Kumada reaction, which consists in coupling a Grignard reagent ( $R-Mg-Hal$ ) and an alkyl
- 25       halide, vinyl halide or aryl halide, and its variants;
- the Stille reaction, which consists in coupling an organostannic compound (for example,  $Ar-SnBu_3$ ) and an organic halide (for example,  $Ar'-Br$ ), and its variants;

- the Hiyama reaction, which consists in coupling an organosilane (for example,  $\text{Ar-SiR}_3$ ) and an organic halide (for example,  $\text{Ar}'\text{-Br}$ ), and its variants; and

- 5                   - the Liebeskind-Srogl reaction, which consists in coupling a boronic acid (for example,  $\text{Ar-B(OH)}_2$ ) and a thiol ester ( $\text{R-CO-S-R}'$ ) so as to obtain a ketone, and its variants.

Coupling reactions involving three  
10 functional groups are in particular the Mannich reaction, which consists in coupling a compound having an active hydrogen with a non-enolizable aldehyde and a primary or secondary amine so as to obtain an aminomethyl compound, the Hantzsch reaction, which  
15 consists in coupling an amine with an aldehyde and an  $\alpha$ -bromo ketone so as to obtain a pyrrole, and the reaction of Bossio et al., which consists in coupling an  $\alpha$ -ketoaldehyde with a carboxylic acid and an isonitrile so as to obtain an oxazole, while a coupling  
20 reaction involving four functional groups is, for example, the Ugi reaction, which consists in coupling a carboxylic acid, a primary amine, a carbonyl compound and an isocyanide so as to obtain an  $\alpha$ -aminocarboxamide.

25                   Moreover, in the compounds of formulae  $\text{E}_1\text{-X}_1\text{-G}_1$  and  $\text{E}_2\text{-X}_2\text{-G}_2$ ,  $\text{E}_1$  represents the residue of a molecule  $\text{M}_1$  for which a first specific antibody  $\text{AC}_1$  is available, while  $\text{E}_2$  can represent the residue of a molecule  $\text{M}_2$  for which a second specific antibody  $\text{AC}_2$  is  
30 available.

These two residues must exhibit antigenic properties similar to those of the molecules  $M_1$  and  $M_2$  from which they are derived, so as to be recognized, respectively, by the antibody  $AC_1$  and by the antibody  $AC_2$ , and to form with them an immunobond, but they must neither impair the progression of the coupling reaction, in particular through steric hindrance, nor interfere in this reaction.


Thus, the molecules  $M_1$  and  $M_2$  are preferably haptenes, i.e. small molecules which, after grafting onto a vector such as a protein (bovine serum albumin,  $\gamma$ -immunoglobulin, etc.) or a polysaccharide, are capable of inducing in the animal the production of antibodies specifically directed against them.

These haptenes can in particular be hydrocarbons such as naphthalene, anthracene, phenanthrene, bicyclo[2.2.2]octane, bicyclo[2.2.2]heptane, 2,2-dimethyl-3-methyl-4,4-dimethylpentane, adamantane, perhydrophenalene and perhydroanthracene, substituted with a reactive function, preferably carboxylic acid, amine or thiol, capable of allowing them, firstly, to be grafted onto the vector and, secondly, to be attached to the functional groups  $G_1$  and  $G_2$  or to the spacer groups when  $X_1$  and  $X_2$  represent such groups. Such hydrocarbons in fact have the advantage of being relatively chemically inert.


However, these haptenes can also be molecules other than hydrocarbons, in which case, if, in the compounds  $E_1-X_1-G_1$  and  $E_2-X_2-G_2$ , the residues of these molecules comprise one or more free functional groups capable of reacting in the operating conditions

under which the coupling reaction is carried out, this or these functional group(s) should be protected with a suitable protective group chosen before the coupling reaction is carried out, i.e. prior to step i) of the method, and then deprotected between steps i) and ii).

Two molecules have been found to constitute haptenes that are particularly advantageous for carrying out the method according to the invention. These are, firstly, histamine, which corresponds to formula (I) below:




and for which it has been possible to obtain several monoclonal antibodies exhibiting a  $K_d$  at least equal to  $10^{-8}$  M and, secondly, homovanillic acid, which corresponds to formula (II) below:



and for which it has been possible to obtain several monoclonal antibodies exhibiting a  $K_d$  at least equal to  $10^{-6}$  M.


Thus, according to a first preferred arrangement of the method according to the invention,  $E_1$  in the compound  $E_1-X_1-G_1$  or  $E_2$  in the compound  $E_2-X_2-G_2$  corresponds to formula (III) below:



5

in which  $R_1$  represents a hydrogen atom or an amine function-protecting group such as, for example, a *tert*-butyloxycarbonyl (BOC) group or benzyl group.

10 According to another preferred arrangement of the method according to the invention,  $E_1$  in the compound  $E_1-X_1-G_1$  or  $E_2$  in the compound  $E_2-X_2-G_2$  corresponds to formula (IV) below:



15

in which  $R_2$  represents a hydrogen atom or an alcohol function-protecting group such as, for example, a silylated group of the dimethyl *tert*-butylsilyl type, dihydropyran or else a benzyl, allyl or acetal group.

20 In the compound  $E_2-X_2-G_2$ , it is possible for  $E_2$  not to represent the residue of a molecule  $M_2$ , but a group capable of forming at least one covalent bond

with the antibody  $AC_1$  in the presence of a coupling agent, in which case this group is advantageously chosen from amine, carboxylic acid, aldehyde, thiol, phenol, alkenyl and azide groups, and photoactivatable groups such as, for example, benzophenone and arylazide groups.

Preferably,  $E_2$  is an amine or thiol group.

As indicated above, in the compounds  $E_1-X_1-G_1$  and  $E_2-X_2-G_2$ ,  $E_1$  and  $E_2$  may be attached to the functional groups  $G_1$  and  $G_2$ , either directly or via spacer groups.

These spacer groups, the only function of which is that of forming a bridge between, firstly,  $E_1$  and the functional group  $G_1$  and, secondly, between  $E_2$  and the functional group  $G_2$ , are either groups devoid of any functional groups such as saturated hydrocarbon groups of the ethylene ( $-(CH_2)_2-$ ), propylene ( $-(CH_2)_3-$ ) or butylene ( $-(CH_2)_4-$ ) type, or the like, or groups comprising one or more functional groups incapable of reacting in the operating conditions under which the coupling reaction is carried out, or else groups comprising one or more functional groups that are protected, prior to the coupling reaction being carried out, with a suitable protective group.

In accordance with the invention, said at least one immunoassay for the compound Z is preferably a solid-phase assay for reasons of simplicity of implementation.

According to a first preferred embodiment of the method according to the invention, since  $E_2$  corresponds, in the compound  $E_2-X_2-G_2$ , to the residue of



a molecule  $M_2$ , said at least one immunoassay for the compound Z is a "sandwich"-type (or two-site) assay and step ii) comprises the following steps:

5           a<sub>1</sub>) bringing the reaction medium obtained at reaction time  $t$  into contact with a solid phase on which the antibody  $AC_1$  is immobilized, so as to obtain the attachment of the compound Z on this solid phase by immunobinding between this antibody and the residue  $E_1$  of this compound;

10           b<sub>1</sub>) bringing the solid phase into contact with a conjugate comprising the antibody  $AC_2$  coupled to a label, so as to obtain the attachment of this conjugate to this solid phase by immunobinding between this antibody and the residue  $E_2$  of the compound Z  
15 attached to said solid phase;

          c<sub>1</sub>) measuring the amount of conjugate attached to the solid phase by means of the label coupled to the antibody  $AC_2$ ; and

          d<sub>1</sub>) determining, on a standard range, the  
20 concentration of the compound Z in the reaction medium at said time  $t$ , from the amount of conjugate thus measured;

said step ii) also comprising one or more operations consisting in washing the solid phase, between steps  
25 a<sub>1</sub>) and b<sub>1</sub>), and between steps b<sub>1</sub>) and c<sub>1</sub>).

This assay therefore uses the two antibodies  $AC_1$  and  $AC_2$ , the antibody  $AC_1$  being immobilized on the solid phase and the antibody  $AC_2$  being coupled to a label.

30           According to another preferred embodiment of the method according to the invention, since  $E_2$

corresponds, in the compound  $E_2-X_2-G_2$ , to a group capable of forming at least one covalent bond with the antibody  $AC_1$ , said at least one immunoassay for the compound Z is an assay of "SPIE-IA" type (Solid-Phase Epitope ImmunoAssay) as described in US-A-5,476,770 [7], and step ii) comprises the following steps:

a<sub>2</sub>) bringing the reaction medium obtained at reaction time  $t$  into contact with a solid phase on which the antibody  $AC_1$  is immobilized, so as to obtain the attachment of the compound Z to this solid phase by immunobinding between this antibody and the residue  $E_1$  of this compound;

b<sub>2</sub>) reacting a coupling agent with the antibody  $AC_1$  immobilized on the solid phase and the group  $E_2$  of the compound Z attached to this solid phase, so as to obtain the formation of one or more covalent bonds between this antibody and this group;

c<sub>2</sub>) denaturing the immunobond which exists between the antibody  $AC_1$  immobilized on the solid phase and the residue  $E_1$  of the compound Z attached to said solid phase, so as to release this residue from this solid phase;

d<sub>2</sub>) bringing the solid phase into contact with a conjugate comprising the antibody  $AC_1$  coupled to a label, so as to obtain the attachment of this conjugate by immunobinding between said antibody and the residue  $E_1$  of the compound Z thus released;

e<sub>2</sub>) measuring the amount of conjugate attached to the solid phase by means of the label coupled to the antibody  $AC_1$ ; and

f<sub>2</sub>) determining, on a standard range, the concentration of compound Z in the reaction medium at said time t, from the amount of conjugate thus measured;

- 5 said step ii) also comprising one or more operations consisting in washing the solid phase, between steps a<sub>2</sub>) and b<sub>2</sub>), b<sub>2</sub>) and c<sub>2</sub>), c<sub>2</sub>) and d<sub>2</sub>), and between steps d<sub>2</sub>) and e<sub>2</sub>).

This assay itself uses only the antibody  
10 AC<sub>1</sub>, but in two different forms: a first form in which it is immobilized on the solid phase and a second form in which it is coupled to a label.

The coupling agent that is used in step b<sub>2</sub>) may be a chemical reactant, in which case it should be  
15 bifunctional, i.e. it should comprise a first functional group capable of reacting with the group E<sub>2</sub> of the compound E<sub>2</sub>-X<sub>2</sub>-G<sub>2</sub>, and a second functional group, identical or different from the first, capable of reacting with the antibody AC<sub>1</sub>.

20 According to whether these functional groups are identical or different, they may be a homobifunctional reagent such as glutaraldehyde, difluorodinitrobenzene, bis(maleimido)hexane or disuccinimidyl suberate, or a heterobifunctional  
25 reagent such as N-succinimidyl-3-3-(2-pyridyldithio)propionate or succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate.

Glutaraldehyde or disuccinimidyl suberate is preferably used.

As a variant, the coupling agent may be irradiation, for example ultraviolet irradiation, when  $E_2$  represents a photoactivatable group.

In step  $c_2$ ), the denaturation of the immunobond that exists between the antibody  $AC_1$  and the residue  $E_1$  of the compound Z can be carried out conventionally by means of an appropriate reagent, or else through the reaction of ultrasound or of heat.

This reagent may be chosen from acids such as HCl, bases such as NaOH, organic solvents such as, for example, alcohols of the methanol type, surfactants, and mineral salts.

Whatever the technique chosen in order to assay the compound Z:

- 15           - the antibody  $AC_1$  and, where appropriate, the antibody  $AC_2$  may be polyclonal or monoclonal antibodies, even though, in general, it is preferable to use monoclonal antibodies because of their greater specificity;
- 20           - the immobilization of the antibody  $AC_1$  on the solid phase can be a passive or active immobilization; thus, this immobilization can be obtained by simple adsorption of said antibody to the surface of the solid phase, by covalent bonding, via  
25 binding molecules such as the avidin-biotin system, or else via a polyhistidine tag associated with the nickel or copper/NTA (nitrilotriacetic acid) complex; when the antibody  $AC_1$  is a monoclonal antibody, its immobilization on the solid phase can also be obtained  
30 via a polyclonal antibody adsorbed beforehand at the surface of this solid phase;

- the solid phase can be any one of the solid phases conventionally used for immunoassays, such as the wall of a tube or of a well of a microtitration plate, a membrane consisting of a plastic such as polystyrene or nitrocellulose, glass beads, magnetic beads and, in general, any surface to which it is possible to attach, passively or actively, an antibody; and

- the label can be an isotope such as iodine 125, chromium 51 or tritium, an enzyme such as horseradish peroxidase, alkaline phosphatase, acetylcholine esterase or glucose oxydase, a luminescent label such as pyrogallol, luminol or isoluminol, a fluorescent label such as fluoresceine, fluoresceine isothiocyanate, rhodamine or cyanin, or else a substance capable of reacting with avidin or streptavidin, such as biotin and its structural analogues; in the latter case, the avidin or streptavidin is itself labelled, for example with an enzyme or a fluorochrome.

Preferably, the antibody  $AC_1$  and, where appropriate, the antibody  $AC_2$  are monoclonal antibodies; the solid phase is the wall of a well of a microtitration plate; the immobilization of the antibody  $AC_1$  is carried out by passive adsorption of this antibody at the surface of this phase and the label is an enzyme, in particular acetylcholine esterase, because of its turnover (16 000 molecules of substrate hydrolyzed per second and per site) which gives the conjugates that contain it a high specific activity.

In accordance with the invention, the method advantageously comprises an operation consisting of dilution of the reaction medium between steps i) and ii).

5                   Moreover, the effects of the candidate operating condition(s) on the coupling reaction is(are) preferably evaluated in step iii) by determining the yield of this reaction from the concentration of compound Z in the reaction medium as determined in step  
10   ii).

This yield can, for example, be calculated by applying the following formula:

$$\text{Yield (\%)} = \left( \frac{[Z] \times f}{[E_1 - X_1 - G_1]} \right) \times 100$$

15   in which:

• [Z] is the concentration of compound Z in the reaction medium as determined in step ii) and f is the dilution factor for this medium when the latter has been subjected to a dilution between step i) and step  
20   ii), while

•  $[E_1 - X_1 - G_1]$  is the initial concentration of compound  $E_1 - X_1 - G_1$  in the reaction medium.

As indicated above, the coupling reaction for which it is desired to screen the operating  
25   conditions can consist in coupling two or more than two functional groups, the number of functional groups involved in this reaction preferably being equal to 2, 3 or 4.




When the coupling reaction consists in  
30   coupling two functional groups  $G_1$  and  $G_2$ , then:

- in step i), the compounds of formulae  $E_1-X_1-G_1$  and  $E_2-X_2-G_2$  are reacted together so as to obtain the formation, in the reaction medium, of a compound Z which corresponds to the formula  $E_1-X_1-G_1-G_2-X_2-E_2$  in which  $X_1$ ,  $X_2$ ,  $E_1$  and  $E_2$  have the same meaning as above and  $G_1-G_2$  represents the group of atoms resulting from the coupling between said functional groups  $G_1$  and  $G_2$ ; while

- in step ii), the concentration of compound Z in the reaction medium is determined by means of a single immunoassay, which is preferably a solid phase assay of "sandwich" type or of "SPIE-IA" type as described above.



When the coupling reaction consists in coupling three functional groups  $G_1$ ,  $G_2$  and  $G_3$ , then:

- in step i), the compounds of formulae  $E_1-X_1-G_1$  and  $E_2-X_2-G_2$  are reacted with a third compound of formula  $E_3-X_3-G_3$  in which  $X_3$  represents a covalent bond or a third spacer group, which may be identical to or different from  $X_1$  and/or  $X_2$ , while  $E_3$  represents either the residue of a third molecule  $M_3$  which is different from  $M_1$  and from  $M_2$  and for which a third specific antibody  $AC_3$  is available, or a group capable of forming a covalent bond with the antibody  $AC_1$  in the presence of a coupling agent on the condition, however, that  $E_2$  does not already represent such a group, so as to obtain the formation, in the reaction medium, of a compound Z corresponding to one of the formulae below:




5

in which  $X_1$ ,  $X_2$ ,  $X_3$ ,  $E_1$ ,  $E_2$  and  $E_3$  have the same meaning as above, and



or



10

represents the group of atoms resulting from the coupling of said functional groups  $G_1$ ,  $G_2$  and  $G_3$ ; while

15 - in step ii), the concentration of compound Z in the reaction medium is determined by means of two different immunoassays.

20 These assays, which may be carried out in parallel, i.e. on two different samples of the reaction medium, or one subsequent to the other on the same sample of the reaction medium, are preferably both carried out in solid phase.



Thus, they may be two "sandwich"-type assays that are carried out using:

- for the first assay, the antibody  $AC_1$  immobilized on the solid phase and the antibody  $AC_2$   
5 coupled to a first label, and

- for the second assay, the antibody  $AC_1$  immobilized on the solid phase and the antibody  $AC_3$  coupled to a second label,  
the first and second labels possibly being identical  
10 when the two assays are carried out in parallel, but having to be different when they are carried out one after the other.




As a variant, the first assay may be an assay of "SPIE-IA" type which is carried out using the  
15 antibody  $AC_1$  as described above, in which case the second assay is a "sandwich"-type assay that is carried out using the antibody  $AC_2$  or the antibody  $AC_3$  coupled to a label, depending on whether, in the compounds  $E_2-X_2-G_2$  and  $E_3-X_3-G_3$ , it is  $E_2$  or  $E_3$  which represents the  
20 group capable of forming one or more covalent bonds with the antibody  $AC_1$  during the "SPIE-IA" assay.

In all cases, the formation of the compound Z in the reaction medium is guaranteed by the similarity of the concentrations of this compound as  
25 determined by the two assays.


When the coupling reaction consists in coupling four functional groups  $G_1$ ,  $G_2$ ,  $G_3$  and  $G_4$ , then:

- in step i), the compounds of formula  $E_1-X_1-G_1$  and  $E_2-X_2-G_2$  are reacted with a third compound  
30 of formula  $E_3-X_3-G_3$  as defined above and a fourth compound of formula  $E_4-X_4-G_4$  in which  $X_4$  represents a

covalent bond or a fourth spacer group, which may be identical to or different from  $X_1$ ,  $X_2$  and/or  $X_3$ , while  $E_4$  represents either the residue of a third molecule  $M_4$  which is different from  $M_1$ , from  $M_2$  and from  $M_3$  and for which a fourth specific antibody  $AC_4$  is available, or a group capable of forming a covalent bond with the antibody  $AC_1$  in the presence of a coupling agent, on the condition, however, that  $E_2$  and  $E_3$  do not already represent such a group, so as to obtain the formation, in the reaction medium, of a compound  $Z$  corresponding to one of the formulae below:



in which  $X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$ ,  $E_1$ ,  $E_2$ ,  $E_3$  and  $E_4$  have the same meaning as above, and



represents the group of atoms resulting from the coupling of said functional groups  $G_1$ ,  $G_2$ ,  $G_3$  and  $G_4$ ;  
5 while

- in step ii), the concentration of compound Z in the reaction medium is determined by means of three different immunoassays.

Here also, these assays can be carried out  
10 in parallel or one after the other and all three are preferably carried out in solid phase. They may be three "sandwich"-type assays or an assay of "SPIE-IA" type followed by two "sandwich"-type assays, the formation of the compound Z in the reaction medium  
15 being, here again, guaranteed by the similarity of the results obtained.

In accordance with the invention, the candidate operating conditions are preferably chosen from the group consisting of solvents, catalysts,  
20 temperature levels, pressure levels, the use of ultrasound, concentrations (of the substances reacted and/or of the catalyst), stoichiometric ratios (between these substances), reaction times and combinations thereof.

25 Thus, the method according to the invention can be used both for screening operating conditions of a single type, such as, for example, catalysts or

temperature levels or pressure levels, and for screening combinations of operating conditions of different types, such as solvent/catalyst, solvent/catalyst/reaction time, temperature/pressure, or catalyst/temperature/pressure combinations, or the like.

In the text above and below, the term "catalyst" is intended to mean any agent which, merely by its presence in the reaction medium, is capable of accelerating the kinetics of a reaction.

This catalyst may be both a chemical catalyst such as, for example, an organic compound, an inorganic base, a metal, a metal salt, a metal oxide or hydride, an organometallic compound, a metal-ligand complex, a halide, or else a combination thereof, etc., and a biological catalyst, it being possible for the latter to be in very diverse forms, and in particular in the form of an organ, of a tissue, of a cell, of a cell fraction, of a cell organelle, of an enzymatic extract, of a molecular complex or else of a simple molecule, for example an isolated and purified enzyme.

The method according to the invention has many advantages. Specifically:

- it makes it possible, so long as at least one molecule capable of being grafted onto a functional group, either directly or via a spacer group, and at least one antibody capable of specifically recognizing this molecule and of binding with it are available, to assay the compound resulting from the coupling of two functional groups, whatever the latter; as a result, it is sufficient to have available some graftable

molecules and some antibodies specific for these molecules in order to be able to screen the operating conditions of a very large number of coupling reactions by means of the method according to the invention;

5                   - it makes it possible to simultaneously test various types of operating conditions, either in parallel or in combination, whether they are qualitative or quantitative conditions;

                  - it is compatible with all catalytic  
10 systems, whether they are chemical or biological;

                  - it requires no operation consisting in purifying the reaction media obtained at the end of the coupling reaction;

                  - it makes it possible to assess the  
15 effects of the operating conditions quantitatively, by making it possible to obtain the yield of the coupling reaction;

                  - it is very sensitive, since it has been found to allow the detection of a concentration of  
20 compound Z down to  $10^{-9}$  M, which makes it possible to implement it using microvolumes of reagents and of solvents;

                  - it is reproducible;

                  - it is simple to carry out and requires no  
25 expensive and/or not readily available equipment;

                  - it makes it possible to carry out screenings at a high rate; thus, its use on a relatively simple automated device, i.e. an automated device that provides washing of the solid phase,  
30 distribution of the substrate for the enzymatic label and reading of the enzyme/substrate reaction, but that

does not provide distribution of the other reagents, has allowed a single experimenter to carry out about a thousand tests per day. This rate can therefore be multiplied by a factor of 10 (i.e. 10 000 tests per day) using devices that allow complete automation of the method according to the invention.

The method according to the invention is therefore particularly suitable for carrying out "high-throughout" screenings.

10                   A subject of the invention is also a kit for carrying out a method of screening the operating conditions of a coupling reaction of at least two functional groups, which comprises suitable amounts:

15                   - of at least two compounds intended to react together:

                  • a first compound of formula  $E_1-X_1-G_1$  in which  $G_1$  represents a first of said at least two functional groups,  $X_1$  represents a covalent bond or a first spacer group and  $E_1$  represents the residue of a first molecule  $M_1$ ; and

20                   • a second compound of formula  $E_2-X_2-G_2$  in which  $G_2$  represents a second of said at least two functional groups,  $X_2$  represents a covalent bond or a second spacer group, which may be identical to or different from  $X_1$ , and  $E_2$  represents the residue of a second molecule  $M_2$  which is different from  $M_1$ ;

                  - of at least two antibodies:

30                   • a first antibody  $AC_1$  specific for the first molecule  $M_1$ , this antibody being optionally attached to a plurality of solid phases; and

- a second antibody AC<sub>2</sub> specific for the second molecule M<sub>2</sub>, this antibody being coupled to a label;

- of a compound Z comprising the chain E<sub>1</sub>-X<sub>1</sub>-G<sub>1</sub>-G<sub>2</sub>-X<sub>2</sub>-E<sub>2</sub> in which X<sub>1</sub>, X<sub>2</sub>, E<sub>1</sub> and E<sub>2</sub> have the same meaning as above, while G<sub>1</sub>-G<sub>2</sub> represents the group of atoms resulting from the coupling of said at least two functional groups; and, optionally:

- of a reagent for visualizing the label, for example a substrate if the label is an enzyme; and
- 10 - of suitably chosen buffers (dilution buffers, rinsing buffers, etc.).

The subject of the invention is also a kit for carrying out a method of screening the operating conditions of a coupling reaction of at least two functional groups, which comprises suitable amounts:

- of at least two compounds intended to react together:

- a first compound of formula E<sub>1</sub>-X<sub>1</sub>-G<sub>1</sub> in which G<sub>1</sub> represents a first of said at least two functional groups, X<sub>1</sub> represents a covalent bond or a first spacer group and E<sub>1</sub> represents the residue of a first molecule M<sub>1</sub>; and

- a second compound of formula E<sub>2</sub>-X<sub>2</sub>-G<sub>2</sub> in which G<sub>2</sub> represents a second of said at least two functional groups, X<sub>2</sub> represents a covalent bond or a second spacer group, that may be identical to or different from X<sub>1</sub>, and E<sub>2</sub> represents a group capable of forming one or more covalent bonds with an antibody specific for the molecule M<sub>1</sub> in the presence of a coupling agent;

- of at least one antibody, this antibody being said antibody specific for the molecule  $M_1$ ;
- of a conjugate comprising said antibody specific for the molecule  $M_1$  coupled to a label;
- 5       - of a compound Z comprising the chain  $E_1-X_1-G_1-G_2-X_2-E_2$  in which  $X_1$ ,  $X_2$ ,  $E_1$  and  $E_2$  have the same meaning as above, while  $G_1-G_2$  represents the group of atoms resulting from the coupling of said at least two functional groups; and, optionally:
- 10       - of a reagent for visualizing the label,
- of a coupling agent,
- of a reagent capable of denaturing an immunobond, and
- of suitably chosen buffers.

15       A subject of the invention is also the use of a screening method or of a kit as defined above, for the screening, in particular the "high-throughput" screening, of catalysts that are useful in a coupling reaction between two functional groups.

20       Besides the above arrangements, the invention also comprises other arrangements which will emerge from the additional description that follows, which relates to examples of embodiments of the method according to the invention that have made it possible

25       to validate both its feasibility and its advantage for the "high-throughput" screening of operating conditions.

          This additional description is given by way of illustration that is in no way limiting, and refers

30       to the attached drawings.



**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 represents, in a diagrammatic form, the various steps of a first embodiment of the screening method according to the invention.

5           Figure 2 shows the results, in terms of reaction yields, expressed as %, of a screening of operating conditions carried out in accordance with the first embodiment of the method according to the invention illustrated in Figure 1.

10           Figure 3 represents, in a diagrammatic form, the various steps of a second embodiment of the method according to the invention.


15           Figure 4 shows the results, in terms of reaction yields, expressed as %, of a screening of operating conditions carried out in accordance with the second embodiment of the method according to the invention illustrated in Figure 3.

20   **EXAMPLES OF EMBODIMENTS OF THE METHOD ACCORDING TO THE INVENTION**

**EXAMPLE 1:**

25           The present example illustrates a first embodiment of the method according to the invention in which:


          - the coupling reaction is the nitroaldolization reaction that is represented by:



- the screening relates to three types of operating conditions taken in combination, i.e. the type of solvent, the type of catalyst and the reaction  
5 time; and

- the concentration of compound Z in the reaction media is determined by a "sandwich"-type solid-phase ELISA assay.


The compound E<sub>1</sub>-X<sub>1</sub>-G<sub>1</sub> corresponds to formula  
10 (V) below:



(V)

15 and results from the coupling of 6-nitrocaproic acid with histamine.

The compound E<sub>2</sub>-X<sub>2</sub>-G<sub>2</sub> itself corresponds to formula (VI) below:



(VI)

and results from the coupling of N-(2-aminoethyl)-3-(4-  
5 formylphenyl)propionamide with homovanillic acid.

The coupling reaction of the compounds E<sub>1</sub>-X<sub>1</sub>-G<sub>1</sub> and E<sub>2</sub>-X<sub>2</sub>-G<sub>2</sub> is carried out using:

- two candidate solvents: tetrahydrofuran (THF) and methylene chloride (CH<sub>2</sub>Cl<sub>2</sub>);
- 10 - twelve candidate catalysts: tetrabutylammonium fluoride (TBAF), potassium fluoride (KF), triethylamine (TEA), pyridine (PYR), diisopropylamine (DIA), diazabicyclooctane (DABCO), diisopropylethylamine (DIEA), diazabicycloundecene (DBU), dimethylaminopyridine (DMAP), sodium methoxide (NaOMe), sodium  
15 hydroxide (NaOH) and potassium carbonate (K<sub>2</sub>CO<sub>3</sub>), and
- four candidate reaction times: 30 minutes, 1 hour, 4 hours and 12 hours.

The immunoenzymatic assay of the compound Z  
20 (of formula E<sub>1</sub>-X<sub>1</sub>-G<sub>1</sub>-G<sub>2</sub>-X<sub>2</sub>-E<sub>2</sub>) produced by the coupling reaction is carried out using:

- a monoclonal antibody directed against histamine (antibody His-31; K<sub>d</sub>: 10<sup>-9</sup> M), which has been immobilized on the walls of the wells of polystyrene

microtitration plates (of capacity equal to 300  $\mu$ l/well) by coating, i.e. by passive adsorption of this antibody at the polystyrene surface;

- a conjugate comprising a monoclonal antibody directed against homovanillic acid (antibody H6-92;  $K_d$ :  $10^{-7}$  M), coupled to acetylcholine esterase (AChE), this conjugate being prepared and stored as described by Taran et al. in *Clin. Chem.*, 1997, 43(2), 363-368 [8]; and
- the visualizing reagent, which comprises a mixture of  $7.5 \times 10^{-4}$  M acetylthiocholine iodide and  $2.5 \times 10^{-4}$  M 5,5'-dithiobis-(2-nitro)benzoic acid (Ellman reagent) in 0.1 M phosphate buffer (pH 7.4), in order to measure the amount of antibody H6-92/AChE conjugate attached to the solid phase.

The adsorption of the antibody His-31 to the surface of the walls of the wells of the microtitration plates was obtained by depositing 100  $\mu$ l of a solution of this antibody at 5  $\mu$ l/ml in 0.05 M phosphate buffer (pH 7.4) into each of these wells and leaving the plates at ambient temperature for 18 hours. Following this, the wells were washed and saturated with 300  $\mu$ l of EIA buffer, and the plates were covered with scotch tape and stored at 4°C until their use.

The method, the various steps of which are shown diagrammatically in Figure 1, is carried out according to the following procedure.

**1) Procedure:****\* Coupling reaction (step A of Figure 1):**

After having protected the secondary amine function carried by the nitrogenous ring of the histamine residue present in the  $E_1-X_1-G_1$  compound (residue  $E_1$ ) with a BOC group ( $GP_1$  in Figure 1), and the hydroxyl function carried by the ring of the homovanillic acid residue present in the compound  $E_2-X_2-G_2$  (residue  $E_2$ ) with a dimethyl *tert*-butylsilyl group ( $GP_2$  in Figure 2), the following are deposited successively in each of the wells of polypropylene microtitration plates (capacity: 300  $\mu$ l/well):

- 50  $\mu$ l of a 5 mM organic solution of the compound  $E_1-X-G_1$ ,
  - 50  $\mu$ l of a 5 mM organic solution of the compound  $G_2-Y-E_2$ , and
  - 25  $\mu$ l of a 1 mM organic solution of a candidate catalyst,
- a single and same solvent (THF or  $CH_2Cl_2$ ) being used in each well.

The microtitration plates are placed in an incubator shaker, at a temperature of 40°C, and are kept there for the desired reaction time.

**\* Stopping the coupling reaction and deprotection (step B of Figure 1):**

The coupling reaction is stopped and the protective groups are removed by adding 125  $\mu$ l of pure trifluoroacetic acid (TFA) to the wells. The plates are shaken for 15 minutes at ambient temperature.

**\* Dilution of the reaction media (step C of Figure 1):**

Each reaction medium is diluted by removing 10  $\mu$ l of this medium and adding it to 1 ml of EIA  
5 buffer (0.1 M phosphate buffer; 0.15 M NaCl; 0.1% BSA; 0.01% sodium azide; pH 7.4) contained in a deep-well plate well (capacity: 2 ml/well).

This operation is repeated twice such that each reaction medium is diluted  $10^6$ -fold.

10

**\* Assaying of compound Z:**

50  $\mu$ l of each diluted reaction medium are deposited in a well of a microtitration plate in which the wall of the wells is coated with the antibody  
15 His-31 (step D of Figure 1).

The plate is shaken for 1 hour at ambient temperature, and then washed 5 times with a washing buffer consisting of a 0.01 M phosphate buffer, pH 7.4, containing 0.05% of Tween<sup>®</sup> 20 (step E of Figure 1).

20 Next, 50  $\mu$ l of a solution of the H6-92/AChE conjugate at 5 Ellman units/ml (EU), one Ellman unit being defined as the amount of enzyme capable of producing an increase in absorbance of one unit over one minute in one ml of Ellman reagent, for an optical  
25 path of one cm at 25°C are deposited in each well (step F of Figure 1).

The plate is shaken for 3 hours at ambient temperature, and then washed 5 times with the washing buffer (step G of Figure 1).

30 200  $\mu$ l of visualizing reagent (RV) are then introduced into each well. The plate is shaken for 1

hour at ambient temperature, at the end of which time the optical density (OD) at 414 nm of the medium contained in each well is measured by means of an automatic reader.

5                   From the OD values thus obtained, the concentration of compound Z for each reaction medium is determined, with reference to a standard range (which makes it possible to relate an absorbance value to a concentration of compound Z), and then the yield of the  
10                   nitroaldolization reaction is determined by means of the formula for calculating the yield mentioned above.

## 2) Results:

                  The results are given in Figure 2, in the  
15                   form of a matrix in which the reaction yields (expressed as %) are symbolized by white, light grey, medium grey or dark grey circles, depending on whether they are between 0 and 10%, between 10 and 30%, between 30 and 50% or between 50 and 70%.

20                   These circles are distributed over 8 lines each corresponding to a candidate reaction time, and over 12 columns each corresponding to a candidate catalyst, the upper 4 lines giving the yields of the reactions carried out in THF, and the lower 4 lines  
25                   giving the yields of the reactions carried out in  $\text{CH}_2\text{Cl}_2$ .


                  Figure 2 shows, for example, that, when the nitroaldolization reaction is carried out for 4 hours in THF, only diazabicyclooctane (DABCO) and dimethyl-  
30                   aminopyridine (DMAP) make it possible to obtain a reaction yield of greater than 50%, whereas, when it is

carried out for the same amount of time in  $\text{CH}_2\text{Cl}_2$ , such a yield is only obtained in the presence of tetrabutylammonium fluoride (TBAF).

5 **EXAMPLE 2:**

This example illustrates a second embodiment of the method according to the invention in which:


- the coupling reaction is the Sonogashira reaction that is represented by:



- the screening relates to two types of operating conditions taken in combination, i.e. the type of solvent and the type of catalyst; and

- the concentration of compound Z in the reaction media is determined by means of a solid-phase immunoenzymatic assay of "SPIE-IA" type.

In this example, the compound  $\text{E}_1\text{-X}_1\text{-G}_1$  corresponds to formula (VII) below:




(VII)



and results from the coupling of 5-hexynoic acid with histamine.

The compound  $E_2-X_2-G_2$  itself corresponds to formula (VIII) below:



(VIII)

The reaction consisting in coupling the compounds  $E_1-X_1-G_1$  and  $E_2-X_2-G_2$  is carried out using:

10           - three candidate solvents: dimethylformamide (DMF), dimethyl sulphoxide (DMSO) and THF;

          - a library of catalysts prepared *in situ* and in which each catalyst corresponds to a combination between:

15       (1) a metal complex M chosen from the complexes M1 to M7 below:

M1:  $Pd_2dba_3$

M2:  $Pd(PPh_3)_4$

M3:  $Pd(OAc)_2$

20       M4:  $PdCl_2(PPh_3)_2$

M5:  $PdCl_2(C_6H_5CN)_2$


M6:  $Pd(NH_3)_4(NO_3)_2$

M7:  $Ni(acac)_3$ , and


(2) a ligand L chosen from the 23 ligands below:

25       • the ligands L1 to L12 corresponding to the formula  $PR_3$  in which R is respectively an *n*-butyl, *n*-octyl, *t*-butyl,  $-CH_2-CH=CH_2$ ,  $-CH_2OH$ ,  $-CH_2CH_2CH_2OH$ ,  $-N(CH_3)_2$ , phenyl, *o*-tolyl,  $-CH=CH_2$ , *o,p*-di- $OCH_3C_6H_3$  or *o*-furyl group;

- the ligands L13 to L17 corresponding to the formula  $R_2P(CH_2)_nPR_2$  in which R is a methyl group and n is equal to 1 or 2 (L13, L14), or R is a phenyl group and n is equal to 1, 2 or 4 (L15, L16, L17);
- the ligand L18 or the ligand DIOP of formula:



- the arsenic complexes L19 and L20 of formula  $AsPh_3$  and  $(Ph_2)As(CH_2)_2As(Ph_2)$ ;
- the imidazoliums L21 to L23 corresponding to the formula:



15

in which R is an ethyl group and R' is a methyl group (L21); R and R' are t-butyl groups (L22); R and R' are 2,6-diisopropylbenzene groups;

- (3) in the presence of a base chosen from diisopropylethylamine (DIEA) and potassium *tert*-butoxide (tBuOK), and of copper salts chosen from copper iodide (CuI) and copper triflate (CuOTf).

The immunoenzymatic assay for the compound Z (of formula  $E_1-X_1-G_1-G_2-X_2-E_2$ ) produced by the coupling reaction is carried out using:

- a monoclonal antibody directed against histamine (antibody His-76;  $K_d$ :  $10^{-8}$  M), which has been immobilized on the wall of the wells of polystyrene microtitration plates (capacity: 300  $\mu$ l/well) by coating, according to a technique similar to that described in Example 1;

- a conjugate comprising this antibody coupled to AChE; and

- the visualizing reagent described in Example 1 for measuring the amount of His-76/AChE conjugate attached to the solid phase.

The method, the various steps of which are shown diagrammatically in Figure 3, is carried out according to the following procedure.

15

**1) Procedure:**

**\* Coupling reaction (step A of Figure 3):**

After having protected the amine function carried by the nitrogenous ring of the histamine residue present in the compound  $E_1-X_1-G_1$  (residue  $E_1$ ) A and the amine function of the compound  $E_2-X_2-G_2$  with BOC groups (GP in Figure 3), the following are deposited successively into each of the wells of polypropylene microtitration plates (equal capacity: 300  $\mu$ l/well) and under an inert atmosphere:

- 5  $\mu$ l of a solvent or of a 16 mM organic solution of a metal complex M,

- 5  $\mu$ l of a solvent or of a 32 mM organic solution of a ligand L,

- 25  $\mu$ l of an organic solution comprising the compound  $E_2-X_2-G_2$  at 160 mM, a copper salt at 6.4 mM, a base at 480 mM, and

5 - 5  $\mu$ l of an 800 mM organic solution of the compound  $E_1-X_1-G_1$ ,  
a single and same solvent (DMF, DMSO or THF) being used for each well.

The plates are placed in an incubator shaker, at a temperature of 25°C, and are left there  
10 for 24 hours.

**\* Stopping the coupling reaction and deprotection (step B of Figure 3):**

The coupling reaction is stopped and the  
15 BOC groups are removed by adding 40  $\mu$ l of pure TFA to each well. The plates are shaken for 1 hour at ambient temperature.

**\* Dilution of the reaction media (step C of Figure 3):**

20 Each reaction medium is diluted by removing 10  $\mu$ l of this medium and adding it to 1 ml of EIA buffer contained in a well of a deep-well plate (capacity: 2 ml/well).

This operation is repeated twice such that  
25 each reaction medium is diluted  $10^6$ -fold.

**\* Assaying of compound Z:**

100  $\mu$ l of each diluted reaction medium are deposited into a well of a microtitration plate in

which the wall of the wells has been precoated with the antibody His-76.

The plates are shaken for 1 hour at ambient temperature, and then washed 5 times with washing  
5 buffer consisting of a 0.01 M phosphate buffer, pH 7.4, containing 0.05% of Tween<sup>®</sup> 20 (step D of Figure 3).

Next, 100  $\mu$ l of a 0.1 M borate buffer (pH 9) and 10  $\mu$ l of a solution of disuccinimidyl suberate (DSS) at 10 mg/ml in DMF are added to each  
10 well.

The plates are shaken for 15 minutes at ambient temperature, and then washed 5 times with the washing buffer (step E of Figure 3).

150  $\mu$ l of 1N NaOH are then deposited into  
15 each well and left to act at ambient temperature for 5 minutes. At the end of this time, the plates are washed 5 times with the washing buffer (step F of Figure 3).

100  $\mu$ l of a solution of the His-76/AChE conjugate at one Ellman unit/ml are introduced into  
20 each well and the plates are shaken at ambient temperature for 1 hour, and then washed 5 times with the washing buffer (step G of Figure 3).

In order to measure the amount of conjugate that is attached to the solid phase, the procedure is  
25 carried out as in Example 1, the measurement of the optical density (OD) at 414 nm being carried out after 30 minutes or 1 hour of enzymatic reaction.

From the OD values thus obtained, the concentration of compound Z for each reaction medium is  
30 determined, with reference to a standard range, and then the yield of the Sonogashira reaction is

determined by means of the same formula as that used in Example 1 above.

## 2) Results:

5           By way of illustration, some of the results are given in Figure 4, in the form of a matrix in which the reaction yields (expressed as %) are symbolized by circles ranging from white to dark grey, according to whether they are between 0 and 10%, between 10 and 20%,  
10   between 20 and 30%, between 30 and 40% or between 40 and 50%.

          These circles are distributed over 8 lines that correspond, for the first, to the absence of metal complex M (line M0) and, for the other 7, to one of the  
15   metal complexes M1 to M7, and over 24 columns that correspond, for the first, to the absence of ligand L (column L0) and, for the other 23, to the ligands L1 to L23.

          The results given in Figure 4 are those  
20   obtained using DMF as solvent, DIEA as base, copper iodide as copper salt, 2% of metal M and 4% of ligand L.

          It may be noted, in the light of these results, that two ligands (L12 and L19) are found to be  
25   the most effective when they are combined with palladium.

## BIBLIOGRAPHY

- [1] Lavastre and Morken, *Angew. Chem. Int. Ed.*, 1999, 38(21), 3163-3165
- 5 [2] Böhm and Herrmann, *Eur. J. Org. Chem.*, 2000, 3679-3681
- [3] Löber et al., *J. Am. Chem. Soc.*, 2001, 123, 4366-4367
- [4] Shaugnessy et al., *J. Am. Chem. Soc.*, 1999, 121,  
10 2123-2132
- [5] Blackmond et al., *Organic Process Research & Development*, 1999, 3(4), 275-280
- [6] Hinderling and Chen, *Angew. Chem. Int. Ed.*, 1999, 38(15), 2253-2256
- 15 [7] US-A-5,476,770
- [8] Taran et al., *Clin. Chem.*, 1997, 43(2), 363-368